Acute Myeloid Leukemia (AML), Rapid Mutation Panel

Acute Myeloid Leukemia (AML), Rapid Mutation Panel

Test Code

12346
81450
CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.
12346
81450
CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.
Ordering Restrictions may apply. Please provide SERVICE AREA INFORMATION to find available tests you can order.
Not offered in Quest Diagnostics Nichols Institute (IFD) – San Juan Capistrano. Please provide SERVICE AREA INFORMATION to find available tests you can order.
In-home collection is not available in your area through Quest Mobile.

Clinical Significance

Acute Myeloid Leukemia (AML), Rapid Mutation Panel - FLT3 testing is established as a prognostic marker associated with poor prognosis (high percentage of bone marrow blast cells, increased risk of relapse from CR, and reduced survival). However, with the advent of FLT3 inhibitors it is now also a test for targeted therapy in AML. The multi-kinase inhibitor Midostaurin, in combination with chemotherapy, is a targeted agent that significantly prolongs survival in patients with newly diagnosed FLT3-mutated AML and was recently approved by the Food and Drug Administration (FDA). Recently, the European LeukemiaNet recommends FLT3 testing (both tyrosine ...

Test Resources

Test FAQ

AML Rapid Mutation Panel

Test Summary

Acute Myeloid Leukemia (AML), Rapid Mutation Panel

Test Details

Includes

  • CEBPA Mutation
    NPM1 Mutation
    FLT3 ITD/TKD
    TP53 Mutation
    c KIT Mutation
    IDH1/IDH2 Mutation
    CEBPA Mutation Analysis
    NPM1 Mutation Analysis
    FLT3 Mutation Analysis
    TP53 Somatic Mutation, Prognostic
    c KIT Mutation Analysis
    IDH1/IDH2 Mutation Analysis

    Mutations detected in FLT3, IDH1 and IDH2 will be communicated directly to clients as soon as available.

Methodology

Next Generation Sequencing (NGS)

Assay Category

This test is not available for New York patient testing.

Reference Range(s)

See Laboratory Report

Alternative Name(s)

Acute Myeloblastic Leukemia,NGS,TKD,Acute Myelocytic Leukemia,fms-like tyrosine kinase 3,CCAAT,Enhancer Binding Protein Alpha,cKit,Nucleophosmin,IDH1,IDH2,Internal tandem duplication,Isocitrate Dehydrogenase,Isocitrate Dehydrogenase 1,Isocitrate Dehydrogenase 2,Kit,Fragment analysis,Sanger PCR,IDH,tumor protein p53,Tyrosine kinase domain,Polymerase Chain Reaction,Wilms' Tumor 1,WT1,Next Generation Sequencing,ITD

LOINC® Codes, Performing Laboratory

Service Area must be determined
CEBPA Mutation
NPM1 Mutation
FLT3 ITD/TKD
TP53 Mutation
c KIT Mutation
IDH1/IDH2 Mutation
CEBPA Mutation Analysis
NPM1 Mutation Analysis
FLT3 Mutation Analysis
TP53 Somatic Mutation, Prognostic
c KIT Mutation Analysis
IDH1/IDH2 Mutation Analysis

Mutations detected in FLT3, IDH1 and IDH2 will be communicated directly to clients as soon as available.

Methodology

Next Generation Sequencing (NGS)
This test is not available for New York patient testing.

Reference Range(s)

See Laboratory Report

Alternative Name(s)

Acute Myeloblastic Leukemia,NGS,TKD,Acute Myelocytic Leukemia,fms-like tyrosine kinase 3,CCAAT,Enhancer Binding Protein Alpha,cKit,Nucleophosmin,IDH1,IDH2,Internal tandem duplication,Isocitrate Dehydrogenase,Isocitrate Dehydrogenase 1,Isocitrate Dehydrogenase 2,Kit,Fragment analysis,Sanger PCR,IDH,tumor protein p53,Tyrosine kinase domain,Polymerase Chain Reaction,Wilms' Tumor 1,WT1,Next Generation Sequencing,ITD
Service Area must be determined

Preferred Specimen(s)

5 mL blood or 3 mL bone marrow collected in an EDTA (lavender-top) tube

Alternative Specimen(s)

Blood or bone marrow collected in: Sodium heparin (green-top) tube • Extracted DNA from CLIA approved lab in leak-proof container

Minimum Volume

3 mL blood • 1 mL bone marrow

Collection Instructions

Please submit completed requisition form with information

Transport Container

EDTA (lavender-top) tube

Transport Temperature

Room temperature

Specimen Stability

  • Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.

Setup Schedule

Service Area must be determined
5 mL blood or 3 mL bone marrow collected in an EDTA (lavender-top) tube
Blood or bone marrow collected in: Sodium heparin (green-top) tube • Extracted DNA from CLIA approved lab in leak-proof container
3 mL blood • 1 mL bone marrow
Please submit completed requisition form with information
EDTA (lavender-top) tube
Room temperature
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Service Area must be determined
Ordering Restrictions may apply. Please provide SERVICE AREA INFORMATION to find available tests you can order.
Not offered in Quest Diagnostics Nichols Institute (IFD) – San Juan Capistrano. Please provide SERVICE AREA INFORMATION to find available tests you can order.
In-home collection is not available in your area through Quest Mobile.
Test Details

Clinical Significance

Test Resources

Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.

The CPT codes provided are based on AMA guidance and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

This material contains content from LOINC® (http://loinc.org). The LOINC Table, LOINC Table Core are copyright © 1995-2019, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license.

The tests listed by specialty and category are a select group of tests offered. For a complete list of Quest Diagnostics tests, please adjust the filter options chosen, or refer to our Directory of Services.

Customize the test information for your Service Area
We'd love your feedback! Take a brief survey.